Search Results - Lalezari, Jacob

Refine Results
  1. 1
    Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

    Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab by Elneil, Sohier, Lalezari, Jacob P., Pourhassan, Nader Z.

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy

    Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy by Hatano, Hiroyu, Lampiris, Harry, Fransen, Signe, Gupta, Soumi, Huang, Wei, Hoh, Rebecca, Martin, Jeffrey N., Lalezari, Jacob, Bangsberg, David, Petropoulos, Christos, Deeks, Steven G.

    Published 2010
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects

    Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects by Hanna, George J., Lalezari, Jacob, Hellinger, James A., Wohl, David A., Nettles, Richard, Persson, Anna, Krystal, Mark, Lin, Pinfang, Colonno, Richard, Grasela, Dennis M.

    Published 2011
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis

    HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 sub-group analysis by Brinson, Cynthia, Lalezari, Jacob, Gulam, Latiff H, Thompson, Melanie, Echevarria, Juan, Treviño-Pérez, Sandra, Stock, David, Samit, Joshi R, George, Hanna J, Lataillade, Max

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    540 HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis

    540 HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis by Brinson, Cynthia, Lalezari, Jacob, Latiff, Gulam H, Thompson, Melanie, Echevarría, Juan, Treviño-Pérez, Sandra, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

    Published 2014
    Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis

    Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis by Lalezari, Jacob, Latiff, Gulam H, Brinson, Cynthia, Echevarria, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

    Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-s... by Einstein, Mark H, Takacs, Peter, Chatterjee, Archana, Sperling, Rhoda S, Chakhtoura, Nahida, Blatter, Mark M, Lalezari, Jacob, David, Marie-Pierre, Lin, Lan, Struyf, Frank, Dubin, Gary

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    1574 Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis

    1574 Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis by Lalezari, Jacob, Latiff, Gulam H, Brinson, Cynthia, Echevarría, Juan, Treviño-Pérez, Sandra, Bogner, Johannes R, Stock, David, Joshi, Samit R, Hanna, George J, Lataillade, Max

    Published 2014
    Get full text Get full text
    Text
    Save to List
    Saved in:
  9. 9
    Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with Asymptomatic HCMV Shedding

    Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infected Men with A... by Lalezari, Jacob P., Aberg, Judith A., Wang, Laurene H., Wire, Mary Beth, Miner, Richard, Snowden, Wendy, Talarico, Christine L., Shaw, Shuching, Jacobson, Mark A., Drew, W. Lawrence

    Published 2002
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  10. 10
    Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection

    Short-Term Monotherapy with IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor, in Patients with Chronic Hepatitis C Virus Infection by Lalezari, Jacob, Asmuth, David, Casiró, Arnaldo, Vargas, Hugo, Lawrence, Shannon, Dubuc-Patrick, Gloria, Chen, Jie, McCarville, Joseph, Pietropaolo, Keith, Zhou, Xiao-Jian, Sullivan-Bólyai, John, Mayers, Douglas

    Published 2012
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  11. 11
    Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody

    Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody by Jacobson, Jeffrey M., Thompson, Melanie A., Lalezari, Jacob P., Saag, Michael S., Zingman, Barry S., D’Ambrosio, Paul, Stambler, Nancy, Rotshteyn, Yakov, Marozsan, Andre J., Maddon, Paul J., Morris, Stephen A., Olson, William C.

    Published 2010
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  12. 12
    Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults

    Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults by Jacobson, Jeffrey M., Lalezari, Jacob P., Thompson, Melanie A., Fichtenbaum, Carl J., Saag, Michael S., Zingman, Barry S., D'Ambrosio, Paul, Stambler, Nancy, Rotshteyn, Yakov, Marozsan, Andre J., Maddon, Paul J., Morris, Stephen A., Olson, William C.

    Published 2010
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  13. 13
    Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study

    Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study by Berkowitz, Elchonon M., Moyle, Graeme, Stellbrink, Hans-Jürgen, Schürmann, Dirk, Kegg, Stephen, Stoll, Matthias, El Idrissi, Mohamed, Oostvogels, Lidia, Heineman, Thomas C., Brockmeyer, Norbert, deJesus, Edwin, Esser, Stefan, Hawkins, Trevor, Lalezari, Jacob, Orkin, Chloe, Schneider, Stefan

    Published 2015
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  14. 14
    Sofosbuvir and Ribavirin for Hepatitis C in Patients with HIV-1 Coinfection

    Sofosbuvir and Ribavirin for Hepatitis C in Patients with HIV-1 Coinfection by Sulkowski, Mark S., Naggie, Susanna, Lalezari, Jacob, Fessel, Walford Jeffrey, Mounzer, Karam, Shuhart, Margaret, Luetkemeyer, Anne F., Asmuth, David, Gaggar, Anuj, Ni, Liyun, Svarovskaia, Evguenia, Brainard, Diana M., Symonds, William T., Subramanian, G. Mani, McHutchison, John G., Rodriguez-Torres, Maribel, Dieterich, Douglas

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  15. 15
    Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

    Maraviroc for Previously Treated Patients with R5 HIV-1 Infection by Gulick, Roy M., Lalezari, Jacob, Goodrich, James, Clumeck, Nathan, DeJesus, Edwin, Horban, Andrzej, Nadler, Jeffrey, Clotet, Bonaventura, Karlsson, Anders, Wohlfeiler, Michael, Montana, John B., McHale, Mary, Sullivan, John, Ridgway, Caroline, Felstead, Steve, Dunne, Michael W., van der Ryst, Elna, Mayer, Howard

    Published 2008
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  16. 16
    Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab

    Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab by Agresti, Nicholas, Lalezari, Jacob P., Amodeo, Phillip P., Mody, Kabir, Mosher, Steven F., Seethamraju, Harish, Kelly, Scott A., Pourhassan, Nader Z., Sudduth, C. David, Bovinet, Christopher, ElSharkawi, Ahmed E., Patterson, Bruce K., Stephen, Reejis, Sacha, Jonah B., Wu, Helen L., Gross, Seth A., Dhody, Kush

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  17. 17
    Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing

    Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing by Wei, Datsen George, Chiang, Vicki, Fyne, Elizabeth, Balakrishnan, Mini, Barnes, Tiffany, Graupe, Michael, Hesselgesser, Joseph, Irrinki, Alivelu, Murry, Jeffrey P., Stepan, George, Stray, Kirsten M., Tsai, Angela, Yu, Helen, Spindler, Jonathan, Kearney, Mary, Spina, Celsa A., McMahon, Deborah, Lalezari, Jacob, Sloan, Derek, Mellors, John, Geleziunas, Romas, Cihlar, Tomas

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  18. 18
    Sorivudine versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial

    Sorivudine versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial by Gnann, John W., Crumpacker, Clyde S., Lalezari, Jacob P., Smith, Jean A., Tyring, Stephen K., Baum, Kenneth F., Borucki, Michael J., Joseph, W. Patrick, Mertz, Gregory J., Steigbigel, Roy T., Cloud, Gretchen A., Soong, Seng-jaw, Sherrill, Lanette C., DeHertogh, Deborah A., Whitley, Richard J., Group, the Collaborative Antiviral Study Group (Casg)/aids Clinical Trials Group (Actg) Herpes Zoster Study

    Published 1998
    Get full text Get full text
    Text
    Save to List
    Saved in:
  19. 19
    All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study

    All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study by Nelson, David R, Cooper, James N, Lalezari, Jacob P, Lawitz, Eric, Pockros, Paul J, Gitlin, Norman, Freilich, Bradley F, Younes, Ziad H, Harlan, William, Ghalib, Reem, Oguchi, Godson, Thuluvath, Paul J, Ortiz-Lasanta, Grisell, Rabinovitz, Mordechai, Bernstein, David, Bennett, Michael, Hawkins, Trevor, Ravendhran, Natarajan, Sheikh, Aasim M, Varunok, Peter, Kowdley, Kris V, Hennicken, Delphine, McPhee, Fiona, Rana, Khurram, Hughes, Eric A

    Published 2015
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  20. 20
    Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

    Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study by Eron, Joseph J., Clotet, Bonaventura, Durant, Jacques, Katlama, Christine, Kumar, Princy, Lazzarin, Adriano, Poizot-Martin, Isabelle, Richmond, Gary, Soriano, Vincent, Ait-Khaled, Mounir, Fujiwara, Tamio, Huang, Jenny, Min, Sherene, Vavro, Cindy, Yeo, Jane, Walmsley, Sharon L., Cox, Joseph, Reynes, Jacques, Morlat, Philippe, Vittecoq, Daniel, Livrozet, Jean-Michel, Fernández, Pompeyo Viciana, Gatell, Jose M., DeJesus, Edwin, DeVente, Jerome, Lalezari, Jacob P., McCurdy, Lewis H., Sloan, Louis A., Young, Benjamin, LaMarca, Anthony, Hawkins, Trevor

    Published 2013
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: